3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lymphoproliferative Disorders
2
Hematologic Neoplasms
2
Melanoma
1
Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
trametinib
1
entrectinib
1
dabrafenib
1
cobimetinib
1
carbon-11 acetate
1
capmatinib
1
Vemurafenib
1
Temozolomide
1
Magnetic Resonance Spectroscopy
1
Lomustine
1
Ga(III)-DOTATOC
1
Disulfiram
1
Copper
1
Carbon-11
1
Alkylating Agents
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Glioma
×
entrectinib
×
Clear all
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled